Quad by MEDVi ED Treatment: What You Need to Know
Quad by MEDVi is a compounded erectile dysfunction (ED) treatment that combines four active pharmaceutical ingredients into a single sublingual tablet or troche. Positioned as a “quad-mix” oral alternative to injectable ED therapies, the product is offered through MEDVi, a telehealth platform that provides consultations, prescriptions, and fulfillment for men's health treatments. The formulation typically includes a combination of sildenafil, tadalafil, oxytocin, and either L-Citrulline or another synergistic agent designed to address ED through multiple pharmacological pathways simultaneously.
Compounded medications occupy a unique regulatory space — they are prepared by compounding pharmacies based on individual prescriptions and are not subject to the same FDA approval process as commercially manufactured drugs. The Quad formulation has generated significant interest among men who have not responded adequately to single-agent PDE5 inhibitors like Viagra or Cialis, or who are seeking a more comprehensive pharmacological approach. However, the combination of multiple active ingredients also raises questions about safety, drug interactions, and whether the clinical rationale justifies the added complexity and cost.
Key Ingredients and How It Works
The Quad by MEDVi formulation combines multiple active pharmaceutical ingredients, each targeting a different aspect of erectile function:
- Sildenafil — A PDE5 inhibitor (the active ingredient in Viagra) that increases blood flow by relaxing smooth muscle tissue in penile blood vessels. Well-established efficacy with decades of clinical evidence.
- Tadalafil — Another PDE5 inhibitor (the active ingredient in Cialis) with a longer half-life than sildenafil, providing a wider window of effectiveness. Combining two PDE5 inhibitors at lower individual doses is the rationale for including both.
- Oxytocin — A neuropeptide sometimes called the “bonding hormone.” Its inclusion targets the central nervous system component of sexual arousal. Evidence for sublingual oxytocin's effect on erectile function is limited and largely preliminary.
- L-Citrulline (or alternative fourth agent) — A dopamine receptor agonist that acts on the brain to promote erection initiation. Previously marketed in some countries as Uprima for ED, it was withdrawn due to limited efficacy and side effects including nausea.
The sublingual delivery route is designed for faster onset compared to oral tablets, as the medication absorbs through the mucous membranes under the tongue and enters the bloodstream without first-pass liver metabolism. The multi-mechanism approach is pharmacologically rational in theory, but the evidence supporting this specific four-drug combination as superior to optimized single-agent therapy is limited.
Benefits
- Multi-mechanism approach — Targets both vascular (PDE5 inhibition) and neurological (dopamine, oxytocin) pathways involved in erectile function.
- Sublingual delivery — Potentially faster onset and improved bioavailability compared to standard oral tablets.
- Telehealth convenience — MEDVi's platform allows consultation, prescription, and delivery without in-person visits, which may reduce barriers for men reluctant to discuss ED with a provider face-to-face.
- Lower individual doses — Combining multiple agents at lower doses may reduce side effects compared to maximum-dose single-agent therapy.
- Option for partial responders — May benefit men who have had incomplete responses to single PDE5 inhibitors alone.
Real User Feedback
User feedback for Quad by MEDVi is generally positive among men who have tried it, with many reporting faster onset, stronger effects, and improved confidence compared to single-agent PDE5 inhibitors. However, this feedback exists primarily on MEDVi's own platform and affiliated review sites, which limits its independence. Some users report side effects including headaches, flushing, nasal congestion, and nausea — the latter likely attributable to the L-Citrulline or oxytocin components. Pricing is a recurring concern in user discussions, as compounded formulations are typically more expensive than generic sildenafil or tadalafil alone. The telehealth consultation process receives mixed reviews, with some users praising its convenience and others questioning the thoroughness of the medical evaluation.
Pricing and Where to Buy
Quad by MEDVi is available exclusively through the MEDVi telehealth platform, which requires an online consultation and prescription:
- Monthly subscription: approximately $89-$149 per month depending on dosage and quantity
- Per-dose pricing: varies based on subscription tier, typically $8-$15 per dose
- Consultation fee: may be included or charged separately depending on the plan
Generic sildenafil (20mg tablets) is available through traditional pharmacies for as little as $1-$3 per dose, which provides important context for evaluating the Quad's value proposition.
Pricing is subject to change. Check the official product listing for current prices.
Pros and Cons
Pros
- Combines established PDE5 inhibitors with central-acting agents for a multi-pathway approach
- Sublingual delivery may offer faster onset than traditional oral tablets
- Telehealth model provides discreet access without in-person physician visits
- May benefit men with partial responses to single-agent PDE5 inhibitors
- Prescription-based — requires at least a telehealth medical evaluation
Cons
- Compounded medications are not FDA-approved and face less regulatory oversight than manufactured pharmaceuticals
- Significantly more expensive than generic single-agent PDE5 inhibitors
- Limited published clinical evidence for this specific four-drug combination
- Telehealth consultations may not be as thorough as in-person evaluations for a condition that can indicate underlying cardiovascular disease
The Bottom Line
Quad by MEDVi represents a pharmacologically interesting approach to erectile dysfunction that combines multiple mechanisms of action into a single sublingual formulation. The inclusion of sildenafil and tadalafil leverages decades of clinical evidence for PDE5 inhibition, while the addition of oxytocin and L-Citrulline targets central nervous system pathways that single-agent treatments do not address. For men who have genuinely tried optimized single-agent therapy and had inadequate results, the multi-mechanism approach has a rational basis.
However, consumers should weigh several important considerations. First, the specific four-drug combination has not been validated in large-scale, peer-reviewed clinical trials comparing it to optimized monotherapy. Second, compounded medications operate in a different regulatory framework than FDA-approved drugs. Third, the cost premium over generic PDE5 inhibitors is substantial. And critically, ED can be an early indicator of cardiovascular disease, diabetes, and other serious conditions — a telehealth consultation, however convenient, may not provide the comprehensive medical evaluation that this symptom warrants. Men experiencing erectile difficulties should prioritize a thorough evaluation with a urologist or primary care physician before exploring compounded multi-drug formulations.
FAQs
Is Quad by MEDVi FDA-approved?
No. As a compounded medication, Quad is prepared by a compounding pharmacy based on an individual prescription and is not subject to the FDA approval process that applies to commercially manufactured drugs. The individual active ingredients (sildenafil, tadalafil) are FDA-approved, but the specific combination product is not.
Why combine two PDE5 inhibitors instead of using a higher dose of one?
The rationale is that combining lower doses of sildenafil (fast onset, shorter duration) with tadalafil (slower onset, longer duration) provides a wider effectiveness window while potentially reducing dose-dependent side effects. However, this approach has not been extensively studied in controlled clinical trials.
Can I take Quad if I am already on blood pressure medication?
PDE5 inhibitors can cause significant blood pressure drops when combined with nitrates and certain antihypertensive medications. This is a potentially dangerous interaction. A thorough medication review with a physician — not just a telehealth screening — is essential before using any PDE5 inhibitor combination product.
How does the cost compare to generic Viagra or Cialis?
Generic sildenafil is available for approximately $1-$3 per dose at many pharmacies, while Quad by MEDVi costs approximately $8-$15 per dose plus subscription fees. The price premium may be justified for some patients, but it is important to ensure that standard-dose single-agent therapy has been genuinely optimized before pursuing more expensive alternatives.
Should I see a urologist before trying Quad?
Yes. Erectile dysfunction can be an early warning sign of cardiovascular disease, diabetes, hormonal imbalances, or neurological conditions. A comprehensive evaluation — including physical examination, lab work, and cardiovascular risk assessment — is medically appropriate before attributing the problem solely to local vascular insufficiency and treating it pharmacologically.
These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease. Always consult your healthcare provider before starting any new supplement. TutelaMedical.com is an independent health research publication — not a medical practice.